We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+65.49%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$2.65B
AUM Growth
+$969M
Cap. Flow
+$186M
Cap. Flow %
7.03%
Top 10 Hldgs %
54.64%
Holding
73
New
13
Increased
31
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.6M
2
WVE icon
Wave Life Sciences
WVE
+$41.8M
3
QTTB icon
Q32 Bio
QTTB
+$30.2M
4
KRRO icon
Korro Bio
KRRO
+$20.3M
5
RLMD icon
Relmada Therapeutics
RLMD
+$20.2M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$37.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12M
4
QDEL icon
QuidelOrtho
QDEL
+$10.8M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.97%
2 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
51
DELISTED
La Jolla Pharmaceutical Company
LJPC
$8.99M 0.34%
2,287,991
+271,722
+13% +$1.6M
CTMX icon
52
CytomX Therapeutics
CTMX
$729M
$8.64M 0.33%
1,039,593
+49,130
+5% +$331K
PHGE icon
53
BiomX
PHGE
$1.94M
$5.81M 0.22%
+3,158
New +$5.44M
ARGX icon
54
argenx
ARGX
$54.3B
$5.1M 0.19%
31,752
+236
+0.7% +$31.9K
PSNL icon
55
Personalis
PSNL
$1.44B
$2.78M 0.1%
255,000
– –
MOTS
56
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$1.78M 0.07%
2,585
+333
+15% +$188K
FLGT icon
57
Fulgent Genetics
FLGT
$526M
$968K 0.04%
+75,000
New +$891K
VRAY
58
DELISTED
ViewRay, Inc.
VRAY
$633K 0.02%
+150,000
New +$485K
TXG icon
59
10x Genomics
TXG
$6.03B
$381K 0.01%
5,000
– –
PHGE.WS
60
DELISTED
BiomX Inc. Warrants to purchase one-half of a share of Common Stock
PHGE.WS
$288K 0.01%
+600,000
New +$374K
CDNA icon
61
CareDx
CDNA
$2.35B
– –
-154,951
Closed -$3.5M
LAB icon
62
Standard BioTools
LAB
$307M
– –
-2,109,500
Closed -$9.77M
OPTN
63
DELISTED
OptiNose
OPTN
– –
-5,854
Closed -$615K
QDEL icon
64
QuidelOrtho
QDEL
$1.19B
– –
-176,495
Closed -$10.8M
SLDB icon
65
Solid Biosciences
SLDB
$859M
– –
-9,703
Closed -$1.5M
STIM icon
66
Neuronetics
STIM
$164M
– –
-167,728
Closed -$1.39M
VIRX
67
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-198,459
Closed -$5M
SILK
68
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-244,716
Closed -$7.96M
QTNT
69
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-32,029
Closed -$9.95M
LVGO
70
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-15,000
Closed -$262K
PRNB
71
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-270,948
Closed -$7.65M
CHAC.U
72
DELISTED
Chardan Healthcare Acquisition Corp.
CHAC.U
– –
-600,000
Closed -$7.18M
1 2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q4 2019 Portfolio in Review

As of Q4 2019, RTW Investments held 73 positions worth $2.65B, up 58% from $1.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $186M of net new capital in Q4 2019, opening 13 new positions and adding to 31 existing holdings. Its largest new stake was Immunovant: 4,426,106 shares worth $66M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $37.9M trimmed.

  • RTW Investments's largest Q4 2019 buy was Immunovant: 4,426,106 shares worth $66M.
  • RTW Investments added most to Q32 Bio in Q4 2019, an estimated $30.2M increase.
  • RTW Investments's biggest Q4 2019 reduction was Achillion Pharmaceuticals, cutting an estimated $37.9M.
  • RTW Investments fully exited QuidelOrtho in Q4 2019, selling an estimated $10.8M.
  • RTW Investments's ten largest holdings make up 55% of its $2.65B portfolio in Q4 2019.
  • RTW Investments opened 13 new positions and closed 12 in Q4 2019.
  • RTW Investments's portfolio value rose 58% quarter-over-quarter to $2.65B.

Based on RTW Investments's 13F filing for Q4 2019, filed 14 Feb 2020.